课题基金 / 基金详情

Development of therapies for overcoming EMT-associated irreversible tyrosine kinase inhibitor resistance in EGFR lung cancer

Development of therapies for overcoming EMT-associated irreversible tyrosine kinase inhibitor resistance in EGFR lung cancer
开发克服 EGFR 肺癌中 EMT 相关不可逆酪氨酸激酶抑制剂耐药性的疗法
批准号:
26860603
负责人:
Fukuda Koji
金额:
$2.41万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Young Scientists (B)
财政年份:
2014
资助国家:
日本
项目状态:
已结题
起止时间:
2014-04-01 至 2016-03-31

项目摘要

项目成果

Fukuda Koji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
HDAC inhibition overcomes crizotinib-resistance by inducing mesenchymal-epithelial reverting transition (MERT) via miR-200c up-regulation in EML4-ALK lung cancer cells.
HDAC 抑制通过 EML4-ALK 肺癌细胞中 miR-200c 上调诱导间充质上皮回复转变 (MERT) 来克服克唑替尼耐药。
DOI: --
发表时间: 2016
期刊:
影响因子: --
作者: [Koji Fukuda, Shigeki Nanjo, Shinji Takeuchi, Tadaaki Yamada, Ryohei Katayama, Kengo Takeuchi, Hiroshi Nishihara, Seiji Yano.]
通讯作者: Seiji Yano.
Susceptibility of cyclin-dependent kinase inhibitor 1 deficient mice to joint destruction of rheumatoid arthritis
  • 批准号:
    20K17998
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
  • 资助金额:
    $2.66万
  • 财政年份:
    2020
  • 负责人:
    Fukuda Koji
  • 依托单位:
Development of treatment to overcome TKI resistance caused by EMT in lung cancer
  • 批准号:
    18K07261
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.75万
  • 财政年份:
    2018
  • 负责人:
    Fukuda Koji
  • 依托单位:
Time Bank governance in community comprehensive care in super aged society
  • 批准号:
    18K01450
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.66万
  • 财政年份:
    2018
  • 负责人:
    Fukuda Koji
  • 依托单位:
Development of ALK-TKI-resistant treatment due to EMT of ALK lung cancer
  • 批准号:
    16K19447
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
  • 资助金额:
    $2.5万
  • 财政年份:
    2016
  • 负责人:
    Fukuda Koji
  • 依托单位:
海外基金